WF
LGND icon

Welch & Forbes’s Ligand Pharmaceuticals LGND Stock Holding History

Welch & Forbes’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-5,049
Closed -$271K – 376
2022
Q3 		$271K Sell
5,049
-1,243
-20% -$73.1K 0.01% 332
2022
Q2 		$351K Hold
6,292
– – 0.01% 311
2022
Q1 		$442K Buy
+6,292
New +$457K 0.01% 300

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Welch & Forbes's LGND Position: Q4 2022 in Review

Welch & Forbes sold out of Ligand Pharmaceuticals (LGND) in Q4 2022, closing a stake of 5,049 shares — an estimated $271K sold.

Welch & Forbes first reported a position in LGND in Q1 2022 and held it in 3 quarters. The position peaked at $442K in Q1 2022. 198 funds tracked by Wall St. Rank hold LGND as of Q4 2022.

  • Welch & Forbes reported no remaining Ligand Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Welch & Forbes sold 5,049 Ligand Pharmaceuticals shares in Q4 2022, an estimated $271K.
  • Welch & Forbes first reported a position in Ligand Pharmaceuticals in Q1 2022 and held it in 3 quarters.
  • Welch & Forbes's Ligand Pharmaceuticals position peaked at $442K in Q1 2022.
  • 198 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2022.

Based on Welch & Forbes's 13F filing for Q4 2022, filed 2 Feb 2023.